Study Details
Full Title
[RMC-6236-304] RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Principal Investigator
Niharika
Mettu
Protocol Number
PRO00119103
NCT ID
NCT07252232
Phase
III
Enrollment Status
Open to Enrollment